Evidence map›Paper›PMID 29119601›Full record

ArticleGenetic epidemiology2017

An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Nicholas B Larson, Zachary C Fogarty, Melissa C Larson, Kimberly R Kalli, Kate Lawrenson, Simon Gayther, Brooke L Fridley, Ellen L Goode, Stacey J Winham

Open access · greenAbstract read
In one paragraph

Article in Genetic epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nicholas B LarsonDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-3468-4215
Zachary C FogartyDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Melissa C LarsonDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Kimberly R KalliDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, United States of America.
Kate LawrensonWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.
Simon GaytherCenter for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.
Brooke L FridleyDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, United States of America.
Ellen L GoodeDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Stacey J WinhamDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-8492-9102
Mayo Clinic in Florida · USCedars-Sinai Medical Center · USMayo Clinic · USMoffitt Cancer Center · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Mayo Clinic Interdisciplinary Women's Health Research ProgramK12HD065987 · NICHD · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2010 to 2023
$6.7M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Functional Analysis of LncRNAs in Epithelial Ovarian CancerR00CA184415 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LAWRENSON, KATE · 2015 to 2017
$720k
The role of X chromosome inactivation in ovarian cancerR03CA212127 · NCI · MAYO CLINIC ROCHESTER · PI WINHAM, STACEY J · 2017 to 2018
$159k
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R00 CA184415NCI NIH HHS R01 CA122443NCI NIH HHS R03 CA212127NICHD NIH HHS K12 HD065987
6 · The paper itself

Abstract

X-chromosome inactivation (XCI) epigenetically silences transcription of an X chromosome in females; patterns of XCI are thought to be aberrant in women's cancers, but are understudied due to statistical challenges. We develop a two-stage statistical framework to assess skewed XCI and evaluate gene-level patterns of XCI for an individual sample by integration of RNA sequence, copy number alteration, and genotype data. Our method relies on allele-specific expression (ASE) to directly measure XCI and does not rely on male samples or paired normal tissue for comparison. We model ASE using a two-component mixture of beta distributions, allowing estimation for a given sample of the degree of skewness (based on a composite likelihood ratio test) and the posterior probability that a given gene escapes XCI (using a Bayesian beta-binomial mixture model). To illustrate the utility of our approach, we applied these methods to data from tumors of ovarian cancer patients. Among 99 patients, 45 tumors were informative for analysis and showed evidence of XCI skewed toward a particular parental chromosome. For 397 X-linked genes, we observed tumor XCI patterns largely consistent with previously identified consensus states based on multiple normal tissue types. However, 37 genes differed in XCI state between ovarian tumors and the consensus state; 17 genes aberrantly escaped XCI in ovarian tumors (including many oncogenes), whereas 20 genes were unexpectedly inactivated in ovarian tumors (including many tumor suppressor genes). These results provide evidence of the importance of XCI in ovarian cancer and demonstrate the utility of our two-stage analysis.

Indexed as

AdultAllelesBayes TheoremCarcinoma, Ovarian EpithelialChromosomes, Human, XFemaleGenes, X-LinkedGenotypeHumansModels, GeneticNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideRNA, NeoplasmSequence Analysis, RNAX Chromosome InactivationRNA, NeoplasmBayesianmixture modelovarian cancerRNA-Seq

Identifiers

PMID29119601
PMCPMC5726546
OpenAlexW2767538835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.